Gregg Lapointe

Gregg Lapointe has served as a member of our Board of Directors since January 2019. Since 2012, Mr. Lapointe has served as Co-Founder and Chief Executive Officer of Cerium Pharmaceuticals, a privately-held biopharmaceutical company. He previously held varying roles at Sigma-Tau Pharmaceuticals, Inc., a privately held biopharmaceutical company, from 2001 through 2012, including Chief Operating Officer from 2003 to 2008 and Chief Executive Officer from 2008 to 2012. From 1996 to 2001, Mr. Lapointe served as Vice President of Operations and Vice President, Controller of AstenJohnson, Inc. (formerly JWI Inc.). Mr. Lapointe previously served as a member of the Board of Directors of SciClone Pharmaceuticals, Inc., Raptor Pharmaceuticals, Inc., ImmunoCellular Therapeutics, Inc., Pharmaceutical Research Manufacturers of America (PhRMA), Plus Therapeutics, Inc., and Questcor Pharmaceuticals, Inc. He currently serves on the Board of Directors of two other public biopharmaceutical companies, Soligenix, Inc. and Rigel Pharmaceuticals, Inc. He holds an MBA from Duke University, a Graduate Diploma in Accountancy from McGill University, a Bachelor of Commerce from Concordia University and is a Certified Public Accountant (Illinois).